Here are Wednesday's biggest analyst calls: Palantir, CoreWeave, Robinhood, Victoria's Secret, Starbucks & more

Wall Street research was broadly constructive, with multiple upgrades and reiterated overweight/outperform ratings across software, healthcare, telecom, and consumer names. Highlights include Wells Fargo raising CoreWeave's price target to $135 from $125, BofA upgrading Victoria's Secret to Buy on mid-to-high-teens EPS growth, and JPMorgan upgrading Telecom Argentina to Overweight on consolidation benefits. Several calls were tied to earnings and guidance, including upgrades on T-Mobile US, Qiagen, Spotify, and Armstrong World, while BofA also turned positive on Elevance, Molina, and Centene as Medicaid margins approach a trough.

Analysis

The common thread is not “good earnings” but a broad re-rating of businesses where either the market underestimated operating leverage or a near-term catalyst is forcing the narrative to catch up. The cleanest second-order winners are the picks-and-shovels and consolidation beneficiaries: CRWV, TEO, LGN, and SLI sit in markets where supply is structurally constrained or industry structure is improving, which should sustain upside even if macro growth stays uneven. By contrast, the more mature compounders (SBUX, TMUS, AWI, QGEN) likely need only modest execution to hold gains, but their upside is narrower because the market already treats them as quality/defensive duration plays.

The most important risk is that several of these calls rely on a single quarter of evidence being extrapolated into a multi-quarter inflection. HOOD, PLTR, and SPOT are especially vulnerable to “good enough” reports that fail to justify higher forward multiples; that creates event-driven downside if usage or monetization fails to accelerate in the next 1-2 quarters. In healthcare managed care, the thesis is more durable but slower-moving: ELV/CNC/MOH can work over 6-18 months, yet the trade will likely be choppy until state rate updates and membership mix data visibly confirm margin normalization.

A notable contrarian angle is that consensus may be underpricing the speed of margin reset in telecom, infrastructure software, and healthcare services while overpricing the durability of the current AI-fueled enthusiasm in single-name tech. CRWV and ZETA could still have room because their bull cases depend on revenue quality inflecting, not just near-term beats, but they are also the most exposed to any disappointment in growth durability. If you want cleaner risk/reward, the best setup is to own names with tangible industry structure change rather than names whose valuation is already being pulled forward by narrative momentum.

Key Decisions for Investors

• Long CRWV vs short a basket of high-multiple AI software names for 1-3 months; the edge is tangible near-term demand-supply tightness, while the short leg is vulnerable to multiple compression if AI spend broadens less than expected.
• Buy TEO on a 2-6 month horizon and pair against a regional telecom/EM basket; consolidation should improve pricing power faster than analysts’ models, but cap the position because political/regulatory delays could stall the rerating.
• Accumulate ELV/CNC/MOH on weakness for 6-12 months; the risk/reward is asymmetric if margin normalization arrives in 2027+, but position sizing should reflect that the catalyst is data-driven and likely slower than the market wants.
• Use event risk to fade overly crowded momentum in HOOD or PLTR with defined downside structures; sell out-of-the-money puts or put spreads after sharp post-earnings strength, because the market is already leaning into a multi-quarter reacceleration story.
• Initiate a long ZETA / short SPOT relative-value trade for 3-6 months; both are narrative-driven, but ZETA has a clearer path to recurring revenue expansion while SPOT still carries the burden of proving operating leverage against high expectations.